Segall Bryant & Hamill LLC Invests $4.52 Million in Bioventus Inc. (NYSE:BVS)

Segall Bryant & Hamill LLC acquired a new position in shares of Bioventus Inc. (NYSE:BVS - Free Report) in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 377,824 shares of the company's stock, valued at approximately $4,515,000. Segall Bryant & Hamill LLC owned about 0.47% of Bioventus at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Royce & Associates LP acquired a new position in shares of Bioventus during the third quarter worth approximately $8,337,000. Renaissance Technologies LLC raised its stake in Bioventus by 401.5% during the 2nd quarter. Renaissance Technologies LLC now owns 503,175 shares of the company's stock valued at $2,893,000 after acquiring an additional 402,841 shares in the last quarter. Los Angeles Capital Management LLC acquired a new position in Bioventus during the 3rd quarter worth $1,714,000. Panagora Asset Management Inc. bought a new position in shares of Bioventus in the second quarter worth $787,000. Finally, Bank of Montreal Can acquired a new position in shares of Bioventus during the second quarter valued at $774,000. 62.94% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms recently weighed in on BVS. Canaccord Genuity Group upped their price objective on shares of Bioventus from $12.00 to $15.00 and gave the stock a "buy" rating in a report on Wednesday, November 6th. Craig Hallum upped their price target on shares of Bioventus from $12.00 to $17.00 and gave the stock a "buy" rating in a research note on Friday, September 27th.

Bioventus Price Performance

Shares of BVS stock traded up $0.20 during mid-day trading on Friday, hitting $11.71. 287,914 shares of the stock traded hands, compared to its average volume of 492,760. The company has a debt-to-equity ratio of 1.85, a quick ratio of 0.99 and a current ratio of 1.41. The company's 50-day simple moving average is $12.05 and its 200-day simple moving average is $8.95. Bioventus Inc. has a twelve month low of $3.77 and a twelve month high of $14.38. The firm has a market cap of $950.27 million, a price-to-earnings ratio of -19.20 and a beta of 0.88.

Bioventus (NYSE:BVS - Get Free Report) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.06. Bioventus had a positive return on equity of 15.61% and a negative net margin of 7.11%. The company had revenue of $138.96 million for the quarter, compared to analysts' expectations of $132.57 million. During the same quarter in the prior year, the company earned $0.05 earnings per share. As a group, equities research analysts expect that Bioventus Inc. will post 0.41 earnings per share for the current year.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.